Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
종목 코드 NAUT
회사 이름Nautilus Biotechnology Inc
상장일Aug 07, 2020
CEOMr. Sujal Patel
직원 수155
유형Ordinary Share
회계 연도 종료Aug 07
주소2701 Eastlake Ave East
도시SEATTLE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호98102
전화12063332001
웹사이트https://www.nautilus.bio/
종목 코드 NAUT
상장일Aug 07, 2020
CEOMr. Sujal Patel
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음